Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,098 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Lung Disease Clear all
Completed Phase 2 Interventional Results available

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

NCT03937479
View directory record Official record
Conditions
COPD
Interventions
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
50
States / cities
Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 15, 2026, 2:27 AM EDT
No Longer Available No phase listed Expanded access

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01784562
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Adempas (Riociguat, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Home Pulmonary Rehabilitation for COPD

NCT03480386
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions
Home Based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 15, 2026, 2:27 AM EDT
Completed No phase listed Observational

Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases

NCT00320151
View directory record Official record
Conditions
Pulmonary Diseases
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
3,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 15, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

ACT With CF Self-Help Toolkit

NCT07436351
View directory record Official record
Conditions
Cystic Fibrosis (CF), Depressive and Anxiety Disorders, Psychological Flexibility
Interventions
ACT with CF Self-Help Toolkit, Waitlist
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Inhaler Trainer Efficacy Study

NCT06461403
View directory record Official record
Conditions
Asthma, Copd, Acute Exacerbation of COPD
Interventions
Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
Device · Other
Lead sponsor
Koronis Biomedical Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 2:27 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 15, 2026, 2:27 AM EDT
Completed No phase listed Observational

ICS/LABA Adherence and COPD Exacerbation

NCT02446041
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

E-Visit for COPD and Smoking Cessation

NCT04155073
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Cigarette Smoking, Telemedicine
Interventions
smoking cessation, early COPD detection, electronic visit, Treatment As Usual
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Inspiration Point-A Digital Pulmonary Rehabilitation Tool Management Interventions

NCT03801330
View directory record Official record
Conditions
COPD
Interventions
Usual Care Pulmonary Rehabilitation Program, Pulmonary Rehabilitation Software-Based Home Program
Other
Lead sponsor
Blue Marble Rehab Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Dawes, West Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 15, 2026, 2:27 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

NCT03639051
View directory record Official record
Conditions
COPD
Interventions
Targeted Lung Denervation (TLD), Optimal Medical Care
Device · Other
Lead sponsor
Nuvaira, Inc.
Industry
Eligibility
40 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Clinical Use Cases Assessment of the Gabi System in Young Children With Underlying Medical Conditions (BRIDGE Study)

NCT05319236
View directory record Official record
Conditions
Cardiac Disease, Respiratory Disease, Congenital Cardiac Defect, Cardiovascular Diseases, Chronic Respiratory Disease, Chronic Cardiopulmonary Disease, Premature Infant Disease
Interventions
Gabi System
Device
Lead sponsor
Gabi SmartCare
Industry
Eligibility
Up to 5 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19

NCT05658536
View directory record Official record
Conditions
Post COVID-19 Condition, Post-COVID-19 Syndrome
Interventions
6-Week Self-Management Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ofatumumab, ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

NCT00698828
View directory record Official record
Conditions
Cachexia
Interventions
Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
50 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Waterbury, Connecticut • Clearwater, Florida • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 15, 2026, 2:27 AM EDT
Completed No phase listed Observational

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

NCT00570544
View directory record Official record
Conditions
COPD, Emphysema
Interventions
tiotropium
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
40 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

NCT00475007
View directory record Official record
Conditions
Emphysema, COPD
Interventions
IBV® Valve System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years to 74 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 15, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Limiting Trunk Flexion as a Self-treatment for Low Back Pain

NCT01830751
View directory record Official record
Conditions
Low Back Pain
Interventions
Restrained Sitting Treatment
Other
Lead sponsor
Liberty Mutual Research Institute for Safety
Industry
Eligibility
30 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 15, 2026, 2:27 AM EDT
Completed No phase listed Observational

Exploring Folk Health Practices in Latinos With Chronic Medical Conditions

NCT00224237
View directory record Official record
Conditions
Diabetes, Hypertension, Asthma, Heart Disease, Stroke, Arthritis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 15, 2026, 2:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 15, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

NCT07576894
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
Interventions
Exercise training
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 2:27 AM EDT